Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.

The Journal of antimicrobial chemotherapy - 1 Sept 2017

Heredia Alonso, Hassounah Said, Medina-Moreno Sandra, Zapata Juan C, Le Nhut M, Han Yingshan, Foulke James S, Davis Charles, Bryant Joseph, Redfield Robert R, Wainberg Mark A

Abstract excerpt

Objectives: To compare the effectiveness of HIV integrase inhibitor monotherapy between raltegravir and dolutegravir as an approach to simplify therapy. Methods: We evaluated and compared the efficacy of 20 week monotherapy with dolutegravir or raltegravir in humanized mice (HSC-NSG) infected with HIVBaL. Plasma HIV RNA was measured by quantitative RT-PCR (limit of detection of 150 copies/45 μL of plasma) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Raltegravir Potassium

Share to Viremia

Source

Open in PubMed Open full text

Identifiers

PMID: 28637235
DOI: 10.1093/jac/dkx195
PMCID: PMC5890682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.PMID 28637235Read ↗

Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysisSemantic proximity Read ↗

Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.Semantic proximity Read ↗

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients.Semantic proximity Read ↗

Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice.Semantic proximity Read ↗

Impact of suboptimal APOBEC3G neutralization on the emergence of HIV drug resistance in humanized miceSemantic proximity Read ↗

Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.Semantic proximity Read ↗

A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapySemantic proximity Read ↗

Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapySemantic proximity Read ↗

Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia with Reverse Transcriptase and Integrase Inhibitors, CD4 <sup>+</sup> T-Cell Recovery, and Viral Rebound upon Interruption of Therapy in a New Model for HIV Treatment in the Humanized Rag2 <sup>−/−</sup> γ <sub>c</sub> <sup>−/−</sup> MouseSemantic proximity Read ↗

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.Semantic proximity Read ↗

The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.Semantic proximity Read ↗

Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.